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BACKGROUND: Combined therapy of metronomic cyclophosphamide, methotrexate and high-dose celecoxib targeting angiogenesis
was used in a phase II trial.
METHODS: Patients with advanced cancer received oral cyclophosphamide 50mg o.d., celecoxib 400mg b.d. and methotrexate 2.5mg
b.d. for two consecutive days each week. Response was determined every 8 weeks; toxicity was evaluated according to CTC version
2.0. Plasma markers of inflammation, coagulation and angiogenesis were measured.
RESULTS: Sixty-seven of 69 patients were evaluable for response. Twenty-three patients had stable disease (SD) after 8 weeks, but
there were no objective responses to therapy. Median time to progression was 57 days. There was a low incidence of toxicities.
Among plasma markers, levels of tissue factor were higher in the SD group of patients at baseline, and levels of both angiopoietin-1
and matrix metalloproteinase-9 increased in the progressive disease group only. There were no changes in other plasma markers.
CONCLUSION: This metronomic approach has negligible activity in advanced cancer albeit with minimal toxicity. Analysis of plasma
markers indicates minimal effects on endothelium in this trial. These data for this particular regimen do not support basic tenets of
metronomic chemotherapy, such as the ability to overcome resistant tumours by targeting the endothelium.
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Chemotherapy for the treatment of metastatic cancer mainly follows
the rationale that when drugs are effective, higher doses of drugs are
even more effective. Unfortunately, this has not produced the
anticipated benefits for common solid tumours such as breast
cancer (Stadtmauer et al, 2000). A re-evaluation of ‘traditional’
chemotherapy dose schedules, notably high intermittent doses, has
occurred recently following the observation that low doses of
chemotherapy given continuously (‘metronomic’ dosing) can be
selectively toxic to proliferating endothelial cells in tumours, which
tend to be resistant to standard episodic scheduling (Kerbel and
Kamen, 2004). This has an impact on tumour angiogenesis and so
tumours resistant to normal bolus doses of chemotherapy may
respond to low chronic doses of cytotoxics and with different classes
of anti-cancer drugs, such as the combination of low-dose
vinblastine chemotherapy and a vascular endothelial growth factor
(VEGF) receptor 2 antibody (Klement et al,2 0 0 0 ) .
Cyclooxygenase (COX) catalyses reactions needed for the
formation of prostaglandins from arachidonic acid. Cyclooxygen-
ase-1 is constitutively expressed and maintains normal cellular
physiological functions such as platelet aggregation and gastric
cytoprotection (Needleman et al, 1986). Isoenzyme COX-2
expression is upregulated in inflammation, human tumour
neovasculature and in neoplastic cells present in human colon,
gastric, breast, prostate, endometrial, skin and lung cancer biopsy
tissue (Masferrer et al, 2000; Gately and Kerbel, 2003). There is
increasing evidence that COX-2 modulates angiogenesis by
augmenting the release of angiogenic peptides such as VEGF,
basic fibroblast growth factor (bFGF) and nitric oxide (Gately and
Kerbel, 2003). Inhibition of COX-2 by non-steroidal anti-
inflammatory drugs (NSAIDs) results in reduced angiogenesis
and downregulation of proangiogenic factors, such as VEGF and
bFGF. Indeed, the incidence of colorectal cancer in patients
taking NSAIDs is significantly lower than in those who are not
(Dubois et al, 1998). A recent study showed that tumour growth
was suppressed by inhibiting angiogenesis with a COX-2 inhibitor
both in vitro and in vivo and this was not seen in normal
endothelial cells (Muraki et al, 2011). There was also a significant
suppression of CD133þ/vascular endothelial growth factor
receptor cells in the circulation by COX-2 inhibition.
Clinically, selective COX-2 inhibition is a more attractive
approach due to the lower risk of gastrointestinal toxicity than
non-selective NSAIDs. Celecoxib is a selective COX-2 inhibitor
(Penning et al, 1997) and is the first COX-2 inhibitor that was
given FDA approval and was approved in the UK in 2000, although
two trials in patients with adenomatous polyps have been halted
prematurely over concerns about its cardiovascular safety
(Solomon et al, 2005). A report of the VICTOR study, which was
a phase III placebo-controlled trial of rofecoxib in non-metastatic
colorectal cancer patients, has demonstrated no effect on overall
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ssurvival (OS) when compared with placebo, but there is a
suggestion of a protective effect against recurrence, though this
was not statistically significant (Midgley et al, 2010).
Combining low-dose chemotherapy with anti-angiogenic drugs
is a rational approach to treating drug-resistant cancers, as it
targets both endothelial cells and mechanisms of angiogenesis.
Accordingly, we hypothesised that a combination of low-dose
chemotherapy with celecoxib could be effective in patients with
advanced cancer who were heavily pre-treated with standard
chemotherapy and consequently likely to have drug-resistant
tumours.
We tested our hypothesis in four different patient groups: breast
cancer, gastrointestinal cancer, melanoma and other cancers
(ovarian, prostate, renal and unknown primary). The main
purpose of the trial was to assess efficacy of the combination in
these patients as well as to provide an assessment of safety.
Additionally, we evaluated the potential for plasma proteins to act
as surrogate angiogenic markers that could be used to monitor
treatment activity or be related to achievement of disease
stabilisation. These were based on literature reports defining the
mechanisms of action in preclinical studies, for example down-
regulation of anti-angiogenic mechanisms (thrombospondin, TSP)
(Lawler, 2002; Bocci et al, 2003), expression of key angiogenic
mediators and cytokines (VEGF (Senger et al, 1993), angio-
poietins-1 and -2 (ANG-1 and ANG-2) (Davis et al, 1996;
Maisonpierre et al, 1997) and interleukin-6 (IL-6)) (Cohen et al,
1996), tissue factor (TF) (Rickles et al, 2003), apoptosis markers
(M30) (Gately and Kerbel, 2003) or proteins expressed by
endothelial cells (Von Willebrand factor(VWF), soluble E-selectin
(sEsel)) (Gehan, 1961; Kerbel and Kamen, 2004) and involved
in vascular remodelling (matrix metalloproteinase-9 (MMP-9))
(Bergers et al, 2000).
MATERIALS AND METHODS
Patient selection
Adult patients with histologically or cytologically confirmed cancer
and evaluable lesions were considered for the study at two clinical
centres. Inclusion criteria included WHO performance status (PS)
0–2 and adequate baseline organ function (absolute neutrophil
count X1.5 10
9 per l, platelet count X100 10
9 per l, bilirubin
p1.5 times upper limit of normal, transaminases o5 times upper
limit of normal and creatinine p150mM). Patients could not have
had radiotherapy, chemotherapy or immunotherapy within the
previous 4 weeks (or 6 weeks for nitrosoureas or mitomycin-C).
Patients were also excluded if they had active symptomatic disease
of the central nervous system, uncontrolled non-malignant disease
or a history of gastrointestinal bleeding in the preceding 6 months.
A history of allergy to any of the trials drugs was also an exclusion
criterion. Patients who had received radiotherapy were included if
their assessable disease was outside the radiation field. Written
informed consent was obtained from all patients before enrolment.
The study was conducted with the approval of the Oxford Research
Ethics Committee.
Treatment
Patients received treatment with cyclophosphamide 50mg o.d. and
celecoxib 400mg b.d. for 7 days each week, with methotrexate
2.5mg b.d. for two consecutive days each week. The doses of
cytotoxic drugs were selected based on a report of another trial,
which utilised the same combination (Colleoni et al, 2002). The
dose of celecoxib selected is the standard therapeutic dose. All the
drugs were administered PO. Treatment was continued until grade
3 or 4 toxicity and if and when this improved to a grade 2 or better,
it was continued with a 25% reduction in the dose of cyclo-
phosphamide and methotrexate. Treatment was stopped altogether
if a further grade 3 toxicity occurred. Treatment was continued
until progressive disease (PD), patient refusal of treatment,
investigator decision or significant intercurrent illness. Palliative
and supportive care for disease-related symptoms was offered to
all participants, but the use of aspirin and non-steroidal
anti-inflammatory drugs was not permitted under the study
protocol.
Evaluations
Toxicity was graded according to the NCI Common Toxicity
Criteria version 2. For grades 1 and 2 events treatment was
continued. Dose adjustments were made in the event of grade 3 or
4 toxicities. Treatment was discontinued until the toxicity resolved
to grade 2 or better and was then restarted with a 25% reduction in
the doses of cyclophosphamide and methotrexate. If a further
grade 3 or 4 toxicity occurred, then treatment was stopped
altogether. Delays of over 2 weeks also led to withdrawal from
the trial.
Tumour response was assessed according to WHO criteria, with
radiological investigations repeated every 8 weeks (Therasse et al,
2000). Time to disease progression was calculated from the date of
starting treatment until the date upon which disease progression
was first recorded. Stable disease (SD) duration of 3 months was
considered a response. Survival was determined from the first day
of treatment until the date of death.
Surrogate markers of tumour angiogenesis
Surrogate markers measured in plasma were MMP-9, VEGF, IL-6,
thromospondin (TSP), apoptosis marker (M30), TF, ANG-1,
ANG-2, VWF and sEsel (commercial ELISAs, e.g. Dako-Patts,
Ely, UK and R&D Systems, Abingdon, UK). Intra-assay coefficients
of variation were o5% and inter-assay coefficients were o10%.
Markers were measured in plasma at baseline, after weeks 4 and 8
of therapy.
Statistical methods
The sample size was selected on the basis that a minimum of
14 patients would ensure that the standard error of the observed
response rate was p0.1 and permit a satisfactory estimate of
response rate, but incorporated an early stopping rule according
to the method of Gehan (1961), with the response rate of interest
set at 20%. This was for each tumour type, but once four main
ones were accrued, the study stopped because of slow recruitment
in other tumour types. Numbers exceed 14, where 1 or more
cases with SD were observed in the in first 14 cases. Descriptive
statistics were generated for efficacy, toxicity and pharmacody-
namic end points. The median time to progression (TTP) was
estimated using Kaplan–Meier survival curves (STATA-1). Angio-
genic marker data were subjected to the Anderson–Darling
distribution test to direct parametric/non-parametric mode of
testing, and is presented as mean and s.d. (when data normally
distributed) or median and inter-quartile range (non-normally
distributed). The w
2 test was used for categorical data; Spearman’s
method was used for correlations. Data between groups were
analysed by t-test or the Mann–Whitney U-test. Data at three time
points were analysed by Friedman’s two-way repeated measures
analysis of variance. The log-rank test was used to compare
survival between patients with progressive and SD. Significance
was assumed if Po0.05. All analyses were performed on Minitab
release 15.
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Patient characteristics
Seventy-four patients with advanced cancer were enrolled, of
whom five patients were not well enough to proceed to treatment.
All patients had PD at baseline. Sixty-nine patients completed at
least 1 week of celecoxib (median duration that patients received
treatment was 10 weeks: range: 1–48 weeks). Fourteen patients
were on study for o8 weeks, 34 were on study between 8 and 16
weeks, 11 were on study between 16 and 24 weeks and 10 patients
were on study for over 24 weeks. The baseline and demographic
characteristics for these 69 patients are shown in Table 1. Most
patients had a PS of 0 or 1. The median age was 60 (range: 30–82).
The majority of patients had multiple sites of metastatic disease of
six different primary origins with the most common disease spread
to liver (39%), lungs (35%) and bone (17%). All patients were
heavily pre-treated with a median of two previous chemotherapy
regimens (range: 1–7) as well as other therapies (Table 1). All 69
patients were assessable for safety. Two patients were excluded
from efficacy evaluation with insufficient data. The first of these
patients had melanoma and was taken off study on the eighth day.
The second of these had prostate cancer and was considered non-
eligible as he was enrolled in the study without the knowledge that
he had life-long asthma, which is an exclusion criterion. He was
admitted to hospital with breathlessness and symptoms of a chest
infection, the investigators become aware of his asthma and the
patient was withdrawn from the study.
Toxicity
As expected, the incidence of grade 3 or 4 haematological toxicities
was low and similarly, other grade 3 or 4 toxicities were rare
(Table 2). One patient with renal cell cancer presented with
agitation and acute onset confusion after 6 weeks on study. This
resolved within 24h and CT of the head was normal. He was
diagnosed with a transient ischaemic attack.
Dose administration and dose intensity
Celecoxib dose was maintained for all patients on the trial, in
keeping with there being no protocol-defined criterion for its
reduction. Methotrexate dose was reduced by 25% for five patients
and cyclophosphamide dose was reduced by 25% for four patients.
There was thus one patient in whom the dose of cyclophosphamide
was not reduced as per protocol.
Tumour response
There were no objective responses, but 23 of 67 patients (34.3%)
evaluable had SD at 12 weeks. The other 44 patients (65.7%)
progressed. Best response by site of disease is shown in Table 3.
The median TTP was 57 days (range: 2–338). Median OS was 226
days (range: 9–846). The TTP of breast cancer patients was longer
than in the other groups (82 days) and the median OS of
melanoma patients was shorter than in the other groups (139
days). Survival by response is shown in Figure 1. Patients with SD
survived longer than those with PD, although this was not quite
statistically significant (P¼0.06).
Table 1 Clinical and demographic details of the patients and details of
previous treatments
Male 23
Female 46
Age (range) 59.5 (30.2–82.2)
Performance status (ECOG)
01 9
13 3
21 0
Unk 7
Previous treatment
Surgery 52
Radiotherapy 31
Hormonal/biological 35
Chemotherapy 50
Prior chemotherapy
Median no prior regimens (range) 2 (1–7)
Abbreviation: ECOG¼Eastern Cooperative Oncology Group.
Table 3 Best response per patient and site of disease
Best response site Not evaluable PD SD Total
Breast 0 10 5 15
GI 0 10 7 17
Renal 0 5 2 7
Melanoma 1 10 4 15
Ovary 0 1 2 3
Prostate 1 5 3 9
Unknown primary 0 3 0 3
Total 2 44 23 69
Abbreviations: GI¼gastrointestinal; PD¼progressive disease; SD¼stable disease.
Table 2 Number of patients with grade 3/4 adverse events considered
to be related to study treatment
Adverse event Grade 3 Grade 4
Neutropaenia 1 0
Lymphopaenia 22 0
Thrombocytopaenia 1 0
Anaemia 2 1
Fatigue 11 0
Neurological 6 0
Lethargy 3 0
Diarrhoea 3 0
Dyspnoea 1 0
Vomiting 1 1
Malaise 1 0
Indigestion 1 0
Ischaemic attack 1 0
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
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Time in years
SD (n=23)
PD (n=44)
NE (n=2)
Figure 1 OS shown by treatment outcome. SD¼stable disease;
PD¼progressive disease; NE¼non-evaluable.
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Results were available for 41 patients (breast cancer: 9,
gastrointestinal cancer: 9, renal carcinoma: 2, melanoma: 11,
ovarian cancer: 3 and prostate cancer: 7). Samples were only taken
from one of the research sites. Table 4 shows changes in the
angiogenic markers at the three time points for those in each of
the two groups. In cross-sectional analysis, levels of ANG-1 were
significantly lower in the PD group compared with the SD group at
baseline. Levels of MMP-9 were higher in the PD group compared
with the SD groups at the third time point only. Levels of TF were
higher in the SD group at all three time points. In serial analysis,
levels of both ANG-1 and MMP-9 increased over the three time
points in the PD group only. There were no other statistically
significant changes.
DISCUSSION
This study was designed to assess tumour response to low-dose
continuous (metronomic) chemotherapy with high-dose celecoxib
in patients with advanced, metastatic cancer and to assess the
effects of the combination on surrogate markers of tumour
angiogenesis and their relation to disease stabilisation. The
combination of cyclophosphamide and methotrexate with celecoxib
is based on the postulated importance of angiogenesis in tumour
growth, the in vitro and in vivo anti-angiogenic and anti-neoplastic
properties of celecoxib and early clinical experience of metronomic
chemotherapy in breast and prostate cancer when standard
maximally tolerated dose of chemotherapy has failed. Combination
therapy resulted in over 4 month’s disease stabilisation in a
minority (34.3%) of patients and was well tolerated with a low
incidence of haematological and non-haematological toxicities. No
excess cardiovascular toxicity was observed, although one patient
experienced a grade 3 ischaemic attack. Patients were enrolled with
high levels of transaminases to include patients with advanced
disease, including liver metastases in which a metronomic
approach may have been a more suitable option than standard
chemotherapy due to lower toxicities. Indeed, there were no
significant grades 3 or 4 hepatic toxicities or discontinuations due
to hepatic toxicity despite both methotrexate and celecoxib being
potentially hepatotoxic drugs.
Clinical experience with metronomic chemotherapy and COX-2
inhibitors is limited, but there have been a number of recent
reports suggesting some activity. Colleoni et al (2002, 2006)
reported results with low-dose chemotherapy in patients with
metastatic breast cancer in two trials. In the earlier trial, clinical
benefit rate (CBR: defined as CRþPRþSD for 24 weeks) was
31.7% and in the second, this was even higher at 41.8%. However,
in the first study, the objective response rate (ORR: defined as
patients demonstrating complete response or partial response on
two separate measurements at least 4 weeks apart) was 19%.
Importantly, almost one-fifth of the patients had not received previous
treatment for metastatic disease. In the second, the ORR was 16.3%,
but almost 40% of patients had been previously untreated for
metastatic disease; in pre-treated patients, the ORR was only 11.8%. In
contrast to our study, the PS of patients was mostly 0 or 1 in both
these studies. Toxicity was generally mild in both trials.
A phase II trial involving treatment with low-dose oral
cyclophosphamide, weekly vinblastine and rofecoxib in 47 patients
with advanced solid tumours reported a CBR of 30% with minimal
toxicity (Young et al, 2006). The ORR was only 13% in a group of
mostly good PS patients. Of the responders, three patients had
Hodgkin lymphoma and two others had been untreated for
metastatic disease.
In a small trial, 35 patients were treated with high-dose celecoxib
and low-dose cyclophosphamide in relapsed or refractory
non-Hodgkin’s lymphoma. The ORR was 37% (Buckstein et al,
2006). Other clinical studies of these drugs in different cancers
have reported varying degrees of success (Needleman et al, 1986;
Masferrer et al, 2000; Pasquier et al, 2010; Muraki et al, 2011),
although many have not demonstrated significant efficacy
(Stempak et al, 2006; Kesari et al, 2007; Steinbild et al, 2007;
Stockhammer et al, 2010).
There have been some clinical trials that have reported
encouraging results with metronomic chemotherapy combined
with other anti-angiogenic drugs. One of these was in breast
cancer, where 46 patients with advanced disease were treated
with metronomic oral capecitabine and cyclophosphamide plus
bevacizumab (Dellapasqua et al, 2008). Objective response rate was
48% with a CBR of 68% and mild toxicities. The results of this trial
were considered to be of sufficient importance that a phase III trial
of this combination is being investigated in Europe. In heavily
pre-treated ovarian cancer, 70 patients were treated with oral
cyclophospamide and bevacizumab and the ORR was 24% with
a CBR of 56% (Garcia et al, 2008).
Recently, there have been some reports that have challenged the
concept of the anti-angiogenic effects of celecoxib (Xu et al, 2011).
The effects of celecoxib in glioma cell lines and xenografts included
induction of VEGF expression at a similar level to that induced by
hypoxia and formation of new blood vessels in vivo. The authors
suggested that cytotoxicity of celecoxib might be due to other
effects, such as those on apoptosis rather than on angiogenesis.
Angiogenic therapies often do not induce tumour regression
and, therefore, identification and validation of soluble markers of
anti-angiogenic activity is essential for successful integration of
Table 4 Plasma angiogenic marker data
Marker
Time
point
Result
(PD)
Result
(s.d.)
P (between
groups)
ANG-1 1 1.0 (0.3–6.0) 5.0 (1.5–28.0) 0.018
2 3.0 (0.5–6.5)* 4.2 (1.2–10.7) 0.297
3 3.0 (0.4–9.0)* 7.0 (2.8–34.5) 0.079
ANG-2 1 7.0 (4.0–9.7) 7.5 (5.0–15.5) 0.264
2 6.0 (4.7–10.0) 13.0 (10.5–18.5) 0.224
3 7.0 (5.2–10.7) 8.0 (5.5–18.0) 0.651
IL-6 1 13.0 (10.5–18.5) 19.0 (10.0–25.0) 0.194
2 15.0 (10.0–22.5) 15.5 (8.5–22.3) 0.947
3 15.5 (5.0–19.5) 15.0 (6.5–57.5) 0.995
M30 1 41.0 (30.0–175.0) 53.0 (30.0–80.0) 0.769
2 41.0 (30.0–147.5) 63.0 (30.0–117.0) 0.841
3 40.0 (30.0–140.0) 50.0 ( 30.0–177.0) 0.995
MMP-9 1 60 (45–71) 50 (40–62) 0.088
2 70 (56–72)* 60 (47–69) 0.095
3 72 (60–74)* 55 (43–61) 0.001
sEsel 1 92.5 (62.5–107.5) 65.0 (52.5–132.5) 0.533
2 92.5 (70.0–125.0) 75.0 (52.5–115.0) 0.321
3 90.0 (70.0–117.0) 70.0 (55.0–92.5) 0.193
TF 1 10.0 (5.3–87.5) 60.0 (21.0–235.0) 0.045
2 13.0 (8.0–79.0) 80.0 (41.0–10180) 0.027
3 19.0 (10.0–64.0) 140.0 (50.0–10180) 0.012
TSP 1 200 (4.5–500.0) 60 (4.4–300) 0.727
2 250 (6.2–500.0) 50 (5.8–287) 0.209
3 250 (112–587) 250 (250–400) 0.671
VEGF 1 450 (125–1900) 500 (100–800 0.989
2 250 (113–1450) 320 (250–750) 0.378
3 280 (200–4500) 400 (130–75000) 0.630
VWF 1 115 (99–144) 112 (103–141) 0.856
2 120 (100–138) 130 (103–146) 0.621
3 112 (93–128) 103 (84–156) 0.977
Abbreviations: ANG-1¼angiopoietin-1; ANG-2¼angiopoietin-2; IL-6¼interleukin-6;
MMP-9¼matrix metalloproteinase-9; PD¼progressive disease; sEsel¼E-selectin;
TF¼tissue factor; TSP¼thrombospondin; VEGF¼vascular endothelial growth
factor; VWF¼Von Willebrand factor. 1, 2 and 3 refer to visit number. Data
presented as median and interquartile range. P-value between groups at each time
point by the Mann–Whitney U-test. Statistically significantly different P-values are
in bold. *Po0.05.
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changes in soluble markers of angiogenesis in an attempt to
correlate changes in these variables with clinical and radiological
response. Of these markers, the only significant difference between
patients with SD and PD at baseline was ANG-1 and TF, both
higher by factors of 5 and 6, respectively, in those whose disease
was stable. Whether this implies a more sensitive vascular bed is
not possible to assess. Serial studies showed that levels of MMP-9
increased in line with disease progression, but were stable in those
whose disease was stable. In other serial analysis, levels of ANG-1
also increased over the three time points in the PD group only.
Surprisingly, levels of other angiogenic cytokines (ANG-2 and
VEGF) failed either to differentiate stable from PD, or to be
influenced by the treatments. Pre-treatment blood levels of VEGF
have been tested in many studies and in general, elevated levels
are indicative of poorer prognosis, but do not predict response to
anti-angiogenic drugs (Sessa et al, 2008).
Exploratory analysis of outcome by response showed clearly that
those with SD had longer survival (Figure 1). As this is a phase II
trial, it could be due to intrinsically slower progression of one
group of patients, but this could also reflect a difference in the
biology and response to therapy, which can only be resolved by
randomisation. In all, 7 out of the 10 patients who had long control
of disease (424 weeks) had either breast or colorectal cancer,
suggesting that the reason for SD may be due to underlying
histology. If those patients who had disease stabilisation for
longer than 16 weeks are also included, then 11 out of 21 patients
had either breast or colon cancer and a further 2 patients had
kidney cancer, all of which are tumour histotypes that may have
a more indolent course. Additionally, there was no difference in
how heavily pre-treated the patients were when the patients with
SD were compared with those with PD, thus ruling out the
possibility that benefit might be greater in less pre-treated
patients.
Our data do not support one of the key postulated mechanisms
of action of metronomic therapy, that is suppression of TSP, and
do not show that VEGF is a good marker for angiogenesis in this
setting. A number of other trials using metronomic chemotherapy
with or without celecoxib have also reported mixed results when
assessing biomarkers of angiogenic activity with most reporting
negative findings. For example, in a trial of low-dose metronomic
vinblastine and cyclophosphamide with celecoxib for paediatric
solid tumours, VEGF, bFGF, sVCAM-1, sICAM-1, endostatin and
TSP were measured (Stempak et al, 2006). The results were highly
variable and no statistically significant relationship between them
and disease progression or maintenance of SD was observed which
is likely to be a reflection of small sample size.
In the trial of low-dose chemotherapy in breast cancer
conducted by Colleoni et al (2002), there was a significant drop
in median VEGF levels comparing baseline to 2 months. There was
no difference in median reductions between responders and
non-responders, but the reduction was significant only in
responders. Overall, the conclusion was that there was no evidence
that baseline serum VEGF is associated with predicting response
and relative change in serum VEGF from baseline to 2 months was
not predictive of response. In a more recent trial in metastatic
breast cancer, there was a 30% reduction in serum VEGF after 2
months in patients with CR or PR and a 14% reduction in patients
with SD. There was no significant reduction in patients with PD
(Colleoni et al, 2006). In a phase II trial of metronomic etoposide
and cyclophosphamide in combination with daily thalidomide
and celecoxib in adults with recurrent malignant gliomas, there
was minimal anti-tumour activity and there were no statistically
significant differences between responders and non-responders in
changes in serum or urine levels of bFGF or VEGF (Kesari et al,
2007).
There is an inconsistent relationship between soluble markers of
angiogenesis and response to anti-angiogenic therapy and the
practical utility of using drug-induced increases in circulating
factors as surrogate biomarkers remains to be demonstrated (Sessa
et al, 2008). The lack of normal reference ranges makes it difficult
to interpret results. The most specific endothelial markers, VWF
and soluble sEsel were, like VEGF and ANG-2, unable to
differentiate disease outcome at baseline or response to treatment.
However, no changes in these endothelial markers imply lack of
damage/dysfunction, suggesting that the therapy is not sufficiently
cytotoxic to this organ. In contrast, increased VWF after therapy
such as steroids and cisplatin is taken as a reflection of vascular
damage (Angles-Cano et al, 1979; Licciardello et al, 1985).
Recently, there has been increasing evidence that tumour
endothelial cells may harbour tumour specific genetic abnormal-
ities and, therefore, may acquire drug resistance (Pasquier et al,
2010). Consequently, detailed pharmacogenetic studies on tumour
endothelial cells will be needed in future trials of metronomic
chemotherapy. There has also been increasing evidence to support
additional mechanisms of action of metronomic chemotherapy
beyond that of the anti-angiogenic paradigm. These include
inhibitory effects on regulatory T cells leading to an increased
anti-tumour immune response, induction of tumour dormancy
and direct effects on cancer cells and cancer stem cells
(Pasquier et al, 2010).
In conclusion, this combination of daily cyclophosphamide,
weekly methotrexate given concurrently with daily celecoxib
provided little anticancer activity in a variety of heavily
p r e - t r e a t e dp a t i e n t sw i t ha d v a n c e ds o l i dt u m o u r s .T h ed a t aw i t h
this particular combination do not support the basic tenets of
metronomic chemotherapy, such as the ability to overcome resistant
tumours by targeting the vessels. There has been some evidence
recently that disputes the anti-angiogenic effects of
COX-2 inhibitors, which might explain why this study among others
have seen only minor or no responses with little or no effects on
vascular markers of angiogenesis. There may, therefore, be more
merit in pursuing combination metronomic therapy trials with drugs
with a more established anti-angiogenic mechanism of action.
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